Finance

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China.

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

The facility, which is set to open amid Biogen’s 50th anniversary, will integrate research and development, technical operations, and commercial teams into one location.

The investment, which is a 25% increase from previous years, will support three new advanced manufacturing facilities, expansions at existing sites, and R&D efforts.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, identifies innovative strategies and solutions for addressing the rising cost of medications and improving patient access.

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, explores practical steps pharmaceutical executives can take to foster better collaboration within their organizations, as well as with external partners like providers and pharmacies.

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective financing rounds.

Company executives provide updates on cancer treatment pelareorep and other elements of the company’s pipeline.

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology therapies, respectively.

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics areas.

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in pharma investing.

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy.

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma.

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in development for H3 K27M-mutant diffuse glioma.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could affect the availability and accessibility of specific medications, particularly for patients relying on direct-to-patient telehealth.

Under terms of the deal, Gubra will receive an initial $350 million payment and could earn up to $1.875 billion more in development and sales milestones for the potential weight loss drug.

In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.